NASDAQ:PCRX - Pacira Biosciences Stock Price, Forecast & News

Pacira Biosciences trades on the NASDAQ under the ticker symbol "PCRX."

Pacira Biosciences Inc (NASDAQ:PCRX) released its quarterly earnings data on Thursday, November, 7th. The company reported $0.48 EPS for the quarter, beating the Zacks' consensus estimate of $0.13 by $0.35. The company earned $104.69 million during the quarter, compared to the consensus estimate of $104.88 million. Pacira Biosciences had a net margin of 0.55% and a return on equity of 10.19%. Pacira Biosciences's quarterly revenue was up 25.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.31 EPS. View Pacira Biosciences' Earnings History.

Pacira Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Pacira Biosciences.

Pacira Biosciences issued an update on its FY 2019 Pre-Market earnings guidance on Thursday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $421-421 million, compared to the consensus revenue estimate of $418.06 million.

12 analysts have issued 12 month price targets for Pacira Biosciences' shares. Their forecasts range from $38.00 to $85.00. On average, they expect Pacira Biosciences' stock price to reach $53.10 in the next twelve months. This suggests a possible upside of 20.8% from the stock's current price. View Analyst Price Targets for Pacira Biosciences.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira Biosciences in the last year. There are currently 1 sell rating, 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pacira Biosciences.

Press coverage about PCRX stock has been trending positive this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pacira Biosciences earned a coverage optimism score of 3.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Pacira Biosciences.

Some companies that are related to Pacira Biosciences include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira Biosciences investors own include Gilead Sciences (GILD), Celgene (CELG), ACADIA Pharmaceuticals (ACAD), Clovis Oncology (CLVS), Micron Technology (MU), Incyte (INCY), Bausch Health Companies (BHC), Exelixis (EXEL), Neurocrine Biosciences (NBIX) and NVIDIA (NVDA).

Pacira Biosciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (0.80%), Legacy Capital Partners Inc. (0.11%), State of Alaska Department of Revenue (0.08%), Louisiana State Employees Retirement System (0.03%) and Nisa Investment Advisors LLC (0.02%). Company insiders that own Pacira Biosciences stock include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Dennis Mcloughlin, Gary W Pace, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Paul J Hastings and Richard Scranton. View Institutional Ownership Trends for Pacira Biosciences.

PCRX stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC and Legacy Capital Partners Inc.. Company insiders that have sold Pacira Biosciences company stock in the last year include Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Dennis Mcloughlin, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Paul J Hastings and Richard Scranton. View Insider Buying and Selling for Pacira Biosciences.

PCRX stock was bought by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System, State of Alaska Department of Revenue and Nisa Investment Advisors LLC. Company insiders that have bought Pacira Biosciences stock in the last two years include Gary W Pace and Mark A Kronenfeld. View Insider Buying and Selling for Pacira Biosciences.

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PCRX stock can currently be purchased for approximately $43.97.

Pacira Biosciences has a market capitalization of $1.83 billion and generates $337.28 million in revenue each year. The company earns $-470,000.00 in net income (profit) each year or $0.29 on an earnings per share basis. Pacira Biosciences employs 518 workers across the globe.View Additional Information About Pacira Biosciences.

The official website for Pacira Biosciences is http://www.pacira.com/.

Pacira Biosciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected]